Trial Profile
An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 16 Sep 2016
Price :
$35
*
At a glance
- Drugs Reslizumab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Therapeutic Use
- Sponsors Ception Therapeutics
- 10 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 May 2011 Results presented at the Digestive Disease Week 2011.
- 30 Sep 2009 Actual patient number (226) added as reported by ClinicalTrials.gov.